Primer Fibromiyalji Sendromunda Oral Magnezyum Tedavisinin Etkinliği

Year 2009, Volume: 10 Issue: 1, 11 - 15, 01.04.2009

Yasemin Turan Hikmet Koçyıgıt Seçil Ekinci Korhan Barış Bayram Alev Gürgan Yasin Altundal Aysenur Atay

Abstract

AMAÇ:Bu çalışmanın amacı, primer fibromiyalji sendromu olan hastalarda oral magnezyum tedavisinin hassasnokta sayısı, ağı şiddeti gibi klinik bulgular ve fonksiyonel kapasite üzerine olan etkilerini araştırmaktır.GEREÇ ve YÖNTEMLER:Yirmi-beş primer fibromiyalji sendromu olan hasta (24 bayan 1 erkek) çalışmayadahil edildi. Hastalar istirahat ve aktivite ağrıları, hassas nokta sayısı ve fonksiyonel kapasite açısındandeğerlendirildi. Fibromiyalji etkinlik sorgulaması ve vizuel analog skala (VAS), sırasıyla fonksiyonel durum veağrı şiddetini değerlendirmek için kullanıldı. Serum ve 24 saatlik idrarda magnezyum seviyesi ölçüldü. Serum veidrar magnezyum düzeyleri Abbott Aeroset autoanaylzer orjinal kiti (Abbott Laboratories, Abbott Park, IL,60064, USA) ile ölçüldü. Hastalar iki ay boyunca magnezyum sitrat (Magnesium Diasporal 600 mg saşe b.i.d.oral) tedavisi aldılar. İki ayın sonunda, tekrar muayene edilip klinik bulguları kaydedildi.BULGULAR:Hastaların yaş ortalaması 44.8 (SS=7.4) yıl ve hastalık süresi ortalama 25.4 (SS=19.2) aydı.Hassas nokta sayısı, ağrı ve fibromiyalji etkinlik sorgulaması skorunda tedavi öncesine göre ikinci ayın sonundaanlamlı iyileşme olduğu gözlendi (p0.05).SONUÇ:Fibromiyalji sendromunun tedavisinde magnezyum sitrat tedavisi hassas nokta sayısı, ağrı vefonksiyonel durum üzerinde etkili ve güvenli olarak bulundu

Keywords

Fibromiyalji sendromu, magnezyum, eser element, klinik bulgular

EFFICACY of ORAL MAGNESIUM TREATMENT on PRIMARY FIBROMYALGIA SYNDROME

Abstract

Objective: The aim of this study was to investigate the effects of oral magnesium treatment on clinical findings such as number of sensitive points, severity of pain and functional capacity in primary Fibromyalgia syndrome patients. Material and Methods: Twenty-five primary fibromyalgia syndrome patients (24 female, 1 male) were enrolled to the study. Patients were examined in terms of pain in rest and activity, number of sensitive points and functional capacity. Fibromyalgia Impact Questionnaire and Visual Analogue Scale (VAS) were used for functional assessment and pain respectively. Serum and twenty-four hour urine magnesium levels were measured. The serum and urine magnesium levels were measured by original kits of Abbott Aeroset autoanaylzer (Abbott Laboratories, Abbott Park, IL, 60064, USA). Patients were administered magnesium citrate (Magnesium Diasporal 600 mg sachets b.i.d. orally) therapy for two months. At the end of two months, patients were reexamined in terms of recorded clinical and laboratory findings. Results: The mean age of patients was 44.8 (SD=7.4) years and the mean duration of disease was 25.4 (SD=19.2) months. There was a significant improvement in number of sensitive points, pain and Fibromyalgia Impact Questionnaire score at the end of two-month therapy (p0.05). Conclusions: In the treatment of Fibromyalgia syndrome, magnesium citrate therapy was found to be safe and efficient on number of sensitive points, pain and functional state.

Keywords

Fibromyalgia syndrome, magnesium, trace element, clinical findings

References

• 1. Bennett RM. The Fibromyalgia Syndrome. In: Kelley WN, Haris ED, Ruddy S, Sledge CB, editors. Textbook of rheumatology. Philadelphia: WB Saunders Company 1997:511-9.
• 2. Wolfe F, Ross K,Anderson J, Russell IJ, Herbert L. The prevalence and characteristics of fibromyalgia in the general population.Arthritis Rheum 1995; 38:1928.
• 3. Krsnich-Shriwise S. Fibromyalgia syndrome: An overview. Phys Ther 1997;77:68-75.
• 4. Romano TJ, Stiller JW. Magnesium deficiency in fibromyalgia syndrome. J Nutr Med 1994;4:165-7.
• 5. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. American Rheumatology criteria for classification of fibromyalgia: report of the Multicenter Criteria Committee.Arthritis Rheum 1990;33: 160-72.
• 6. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-34.
• 7. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the fibromyalgia impact questionnaire. Rheumatol Int 2000;20: 9-12.
• 8. Percival M. Fibromyalgia Nutritional Support. Clinical Nutritional Insights 1997:3.
• 9. Heaton FWY. Magnesium deficiency and membrane properties. In: Altura BM, Durlach J, Seelig MS, editors. Magnesium in cellular processes and medicine. Basel: Karger 1987:121-30.
• 10. Yunus MB, Raman KIUP, Raman KK. Primary fibromyalgia syndrome and myofacial pain syndrome: Clinical features and muscle pathology.Arch Phys Med Rehabil 1988;69:451-4.
• 11. Johansson BW. Magnesium infusion in decompensated hypomagnesaemia patients. Acta Pharmacol Toxicol (Copen) 1984;54:125-8.
• 12. Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991;337:747-60.
• 13. Galland L. Magnesium and inflammatory bowel disease. Magnesium 1988;7:78-83.
• 14. Durlach J, Lutfalla G, Poenaru S, Reba A, Henrotte JG, Fabiani F, et al. Latent tetany and mitral valve prolapse due to chronic primary magnesium deficit. In: Halpern MJ, Durlach J, editors. Magnesium defiency. Basel: Karger 1985:102-12.
• 15. Galland L. Magnesium defiency in mitral valve prolapse. In: Halpern MJ, Durlach J, eds. Magnesium defiency. Basel: Karger 1985:117-19.
• 16. Fernandes JS, Pereira T, Alcazar A, Franca A, Andrade R, Pereira JN, et al. Idiopathic mitral valve prolapse and the neuromuscular form of primary magnesium deficit. In: Halpern MJ, Durlach J, editors. Magnesium defiency. Basel: Karger. 1985:120-1.
• 17. Altura BM. Calcium antagonist properties of magnesium: implications for antimigraine actions. Magnesium 1985;4:169-75.
• 18. Abraham GE. Primary dysmenorrhea. Clin Obs Gyn 1978;21:139.
• 19. Abraham GE, Flechas JD. Management of fibromyalgia: Rationale for the use of magnesium and malicAcid. J Nutr Med 1992;3:49-59.
• 20. Eisinger J, Zakarian H, Pouly E, Plantamura A, Ayavou T. Protein peroxidation, magnesium deficiency and fibromyalgia. Magnes Res 1996; 9(4):313-6.
• 21. Eisinger J, Plantamura A, Marie PA, Ayavou T. Selenium and magnesium status in fibromyalgia. Magnes Res 1994;7(3-4):285-8.
• 22. Magaldi M, Moltoni L, Biasi G, Marcolongo R. Changes in intracellular calcium and magnesium ions in the physiopathology of the fibromyalgia syndrome. Minerva Med 2000;91(7-8):137-40
• 23. Prescott E, Norrgard J, Rotbol Pedersen L, Danneskiold-Samsoe B. Fibromyalgia and magnesia. Scand J Rheumatol 1992;21(5): 264.
• 24. Goldenberg DL. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 1997;9(2):135-43.
• 25. Keenoy BM, Moorkens G, Vertommen J, Noe M, Neve J, De Leeuw I. Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium. J Am Coll Nutr 2000;19(3):374-82.
• 26. Clague JE, Edwards RHT, Jackson MJ. Intravenous magnesium loading in chronic fatigue syndrome. Lancet 1992;340: 124-5
• 27. Wahner-Roedler DL, Eklin PL, Vincent A, Thompson JM, Oh TH, Loehrer LL, et al. Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program at a tertiary care center. Mayo Clin Proc 2005; 80(1):55-60.
• 28. Holdcraft LC, Assefi N, Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003;17(4):667-83.
• 29. Sarac AJ, Gur A. Complementary and alternative medical therapies in fibromyalgia. Curr Pharm Des 2006;12(1):47-57.